Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Telo Genomics Corp V.TELO

Alternate Symbol(s):  TDSGF

Telo Genomics Corp. is a biotech company pioneering the telomere platform in the industry with applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. The Company's lead application, TELO-MM is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. Its clinical studies and product development design includes TeloView SMM, TeloView Test to Predict Patient Resistance to Treatment, development in collaboration with the Mayo Clinic and TeloView Test to monitor minimal residual disease in MM patients. The Company, by combining quantitative analysis of three-dimensional telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, is developing products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers.


TSXV:TELO - Post by User

Bullboard Posts
Comment by toto3321on Apr 06, 2017 10:36am
125 Views
Post# 26085389

RE:house one

RE:house one
Hey Nortzy, I tend to agree with you, it looks like someone is determined to keep the share price at these levels. It could also be the 35 cents PP shares being sold, like another poster previously suggested. Although frustrating to look at, I believe it will turn out profitable to those who are patient enough to wait for things to unfold. Having Knight therapeutics involved financially in the company is quite reassuring to me. They must believe that 3DS technology is viable and promising. 
I first got into this stock on the AD news (I was late to the party and gor my shares for 86 cents, not so proud of this...). Having worked with a group of researchers looking for ways to identify the onset/early signs of the disease, I truly believe in the value of 3DS tech (if what they claim is proven reliable). As life expectancy increases, combined with population aging, AD prevalence continues to rise. By detecting AD in its early stages, it is now possible to slow down its progression. For me, just the AD test is enough to justify the current company's market cap. Adding all the other tests makes this co. wayyyy undervalued.
 
JMHO, of course... GLTA, toto
Bullboard Posts